Dyne Therapeutics (NASDAQ:DYN) Downgraded by StockNews.com

StockNews.com lowered shares of Dyne Therapeutics (NASDAQ:DYN) from a hold rating to a sell rating in a research report sent to investors on Monday morning.

Several other research analysts have also weighed in on DYN. HC Wainwright reiterated a buy rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Guggenheim raised their price objective on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a buy rating in a research report on Thursday, August 15th. Chardan Capital upped their target price on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the company a buy rating in a research report on Tuesday, May 21st. Oppenheimer reaffirmed an outperform rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Finally, Stifel Nicolaus boosted their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a buy rating in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $51.40.

Dyne Therapeutics Trading Down 0.8 %

Shares of DYN stock opened at $34.34 on Monday. Dyne Therapeutics has a twelve month low of $6.40 and a twelve month high of $47.45. The company’s 50-day moving average price is $41.38 and its 200-day moving average price is $33.47. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of -8.65 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.02. As a group, equities research analysts predict that Dyne Therapeutics will post -2.96 EPS for the current year.

Insider Buying and Selling

In other news, COO Susanna Gatti High sold 10,163 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the completion of the transaction, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at $5,256,821.36. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, COO Susanna Gatti High sold 10,163 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $35.33, for a total transaction of $359,058.79. Following the completion of the transaction, the chief operating officer now owns 148,792 shares in the company, valued at $5,256,821.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John Cox bought 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the acquisition, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. The disclosure for this purchase can be found here. 20.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC boosted its position in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares during the period. Amalgamated Bank lifted its stake in Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after buying an additional 796 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after acquiring an additional 1,291 shares during the period. Public Employees Retirement Association of Colorado purchased a new position in shares of Dyne Therapeutics during the second quarter worth approximately $203,000. Finally, Farallon Capital Management LLC acquired a new position in shares of Dyne Therapeutics in the 2nd quarter valued at $212,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.